Abstract

Objective

To assess the changes in survival outcomes among patients with anaplastic thyroid carcinoma in the US over the past two decades.

Methods

Surveillance, Epidemiology, and End Results (SEER) database research data were reviewed, and patients with anaplastic thyroid carcinoma, who were diagnosed from 2004 to 2020 were evaluated. Kaplan-Meier survival estimates were conducted to examine differences in overall survival between three year-of-diagnosis groups (2004 to 2010; 2011 to 2016; and 2017 to 2020). Multivariable Cox regression analysis was then performed to explore the factors affecting overall survival.

Results

A total of 1804 patients with anaplastic thyroid carcinoma were included. Using Kaplan-Meier survival estimates, overall survival was better among patients diagnosed from 2017 to 2020 versus those diagnosed at earlier periods (P < 0.001). One-year survival estimates were 25% among patients diagnosed from 2017 to 2020 versus 15% for patients diagnosed from 2011 to 2016, and 19%, for patients diagnosed from 2004 to 2010. Using the multivariable Cox regression model, an earlier year of diagnosis was associated with worse overall survival compared to the diagnosis year 2017 to 2020 (HR for diagnosis 2004 to 2010 versus diagnosis 2017 to 2020: 1.170; 95% CI: 1.029 to 1.331, and HR for diagnosis 2011 to 2016 versus diagnosis 2017 to 2020: 1.251; 95% CI: 1.103 to 1.419).

Conclusions

While anaplastic thyroid carcinoma remains a deadly cancer, survival seems to be improving for the last few years compared to earlier years. There is still additional work to be done to improve the outcomes of those patients.

中文翻译：

---

过去二十年甲状腺未分化癌患者预后的变化

摘要

客观的

评估过去二十年来美国甲状腺未分化癌患者生存结果的变化。

方法

回顾了监测、流行病学和最终结果（SEER）数据库研究数据，并对 2004 年至 2020 年诊断的甲状腺未分化癌患者进行了评估。 Kaplan-Meier 生存估计旨在检查三年诊断组（2004 年至 2010 年、2011 年至 2016 年和 2017 年至 2020 年）之间总体生存率的差异。然后进行多变量Cox回归分析以探讨影响总体生存的因素。

结果

总共纳入了 1804 名未分化甲状腺癌患者。使用 Kaplan-Meier 生存估计，2017 年至 2020 年诊断的患者的总体生存率优于早期诊断的患者 ( P  < 0.001)。 2017 年至 2020 年诊断的患者的一年生存率为 25%，2011 年至 2016 年诊断的患者为 15%，2004 年至 2010 年诊断的患者为 19%。使用多变量 Cox 回归模型，诊断较早的一年与 2017 年至 2020 年诊断年份相比，总体生存率较差（2004 年至 2010 年诊断的 HR 与 2017 年至 2020 年诊断的 HR：1.170；95% CI：1.029 至 1.331，2011 年至 2016 年诊断的 HR 与 2017 年至 2020 年诊断的 HR： 1.251；95% CI：1.103 至 1.419）。

结论

虽然甲状腺未分化癌仍然是一种致命的癌症，但与前几年相比，过去几年的生存率似乎有所改善。为了改善这些患者的治疗结果，仍有许多工作要做。